Walking Fish Therapeutics Launches With $50 Million In Series A Financing To Accelerate Development Of B Cell Therapies For Multiple Diseases
Walking Fish Therapeutics Launches With $50 Million In Series A Financing To Accelerate Development Of B Cell Therapies For Multiple Diseases
09/13/21, 12:05 PM
Location
san franciscoMoney raised
$50 million
Industry
biotechnology
science and engineering
health care
Round Type
series a
Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
Company Info
Location
san francisco, california, united states
Additional Info
A leader in B cell medicines, Walking Fish Therapeutics has made critical advances in engineering technologies to rapidly advance cell-based therapeutics to treat serious diseases, concentrating on oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. For more information and important updates, please visit https://www.walkingfishtx.com/